



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 March 2025
EMA/HMPC/234780/2024
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Crataegus monogyna* Jacq. (Lindm.), *C. laevigata* (Poir.) DC. or their hybrids; *C. pentagyna* Waldst. et Kit. ex Willd.; *C. azarolus* L.

Draft – Revision 1

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Al Makedessi S, Sweidan H, Dietz K, Jacob R. Protective effect of *Crataegus oxyacantha* against reperfusion arrhythmias after global no-flow ischemia in the rat heart. *Basic Res Cardiol* 1999, 94: 71-77

Ammon HPT, Händel M. Crataegus, Toxikologie und Pharmakologie. Teil III: Pharmakodynamik und Pharmakokinetik. *Planta Med* 1981, 43: 313-322 [in German]

Asher GN, Viera AJ, Weaver MA, Dominik R, Caughey M, Hinderliter AL. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial. *BMC Complement Altern Med* 2012, 12: 26

Blaschek W, Hilgenfeldt U, Holzgrabe U, Reichling J, Ruth P, Schulz V, editors. HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen. Version 10.3. Springer Verlag, Berlin Heidelberg 2011

Blaschek W, Hilgenfeld U, Holzgrabe U, Mörike K, Reichling J, Ruth P, editors. HagerROM. Hagers Enzyklopädie der Arzneistoffe und Drogen, Arnicae flos. *Wissenschaftliche Verlagsgesellschaft Stuttgart* 2021

Bleske BE, Zineh I, Hwang HS, Welder GJ, Ghannam MMJ, Boluyt MO. Evaluation of hawthorn on immunomodulatory biomarkers in a pressure overload model of heart failure. *Med Sci Monit* 2007, 13(12): 255-258

Bödighheimer K, Chase D. Wirksamkeit von Weißdorn-Extrakt in der Dosierung 3 mal 100 mg täglich. *Münch Med Wochenschr* 1994, 136(Suppl. 1): 7-11 [in German]

Brixius K, Frank K, Münch G, Müller-Ehmsen J, Schwinger RHG. WS 1442 (Crataegus Spezialextrakt) wirkt am insuffizienten menschlichen Myokard Kontraktionskraft-steigernd. *Herz Kreislauf* 1998, 30:28-33 [in German]



- Brixius K, Willms S, Napp A, Tossios P, Ladage D, Bloch W et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. *Cardiovasc Drugs Ther* 2006, 20(3): 177-184
- Chang Q, Zuo Z, Harrison F, Chow MS. Hawthorn. *J Clin Pharmacol* 2002, 42(6): 605-612
- Chang Q, Zuo Z, Ho WK, Chow MS. Comparison of the pharmacokinetics of hawthorn phenolics in extract versus individual pure compound. *J Clin Pharmacol* 2005a, 45(1): 106-112
- Chang WT, Dao J, Shao ZH. Hawthorn: Potential roles in cardiovascular disease. *Am J Chin Med* 2005b, 33(1): 1-10
- Cicero AFG, Colletti A, von Haehling S, Vinereanu D, Bielecka-Dabrowa A, Sahebkar A. Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). *Nutr Res Rev* 2020, 33: 155-179
- Cloud A, Vilcins D, McEwen B. The effect of hawthorn (*Crataegus* spp.) on blood pressure: A systematic review. *Adv Integr Med* 2020, 7(3): 167-175
- CPMP/EWP/235/95 Rev. 1. Committee for proprietary medicinal products (CPMP) Note for guidance on clinical investigation of medicinal products for the treatment of cardiac failure. Available at: www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003364 [accessed 01/2016]
- Cui M, Cheng L, Zhou Z, Zhu Z, Liu Y, Li C et al. Traditional uses, phytochemistry, pharmacology, and safety concerns of hawthorn (*Crataegus* genus): A comprehensive review. *J Ethnopharmacol* 2024; 30; 319(Pt 2):117229
- Czygan FC. Crataegus als Kardiakum. Ein kurzer kulturhistorischer Rückblick. *Pharm Unserer Zeit* 2005, 34(1): 10-13 [in German]
- Dalli E, Colomer E, Tormos MC, Cosín-Sales J, Milara J, Esteban E et al. *Crataegus laevigata* decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial. *Phytomedicine* 2011a, 18(8-9): 769-775
- Dalli E, Vallés J, Cosín-Sales J, Santos MT, Moscardó A, Milara J et al. Effects of hawthorn (*Crataegus laevigata*) on platelet aggregation in healthy volunteers. *Thromb Res* 2011b, 128(4): 398-400
- Daniele C, Mazzanti G, Pittler MH, Ernst E. Adverse event profile of *Crataegus* spp.: A systematic review. *Drug Saf* 2006, 29(6): 523-535
- Dasgupta A, Kidd L, Poindexter BJ, Bick RJ. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. *Arch Pathol Lab Med* 2010, 134: 1188-1192
- Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); Hawthorn. Drug Levels and Effects. [Updated 2021] Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501831> [assessed 02/2024]
- Edwards JE, Brown PN, Talent N, Dickinson TA, Shipley PR. A review of the chemistry of the genus *Crataegus*. *Phytochemistry* 2012, 79: 5-26
- Eggeling T, Regitz-Zagrosek V, Zimmermann A, Burkart M. Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure - A pooled analysis of clinical trials. *Phytomedicine* 2011, 18: 1214-1219

- Eichstädt H, Bäder M, Danne O, Kaiser W, Stein U, Felix R. Crataegus-Extrakt hilft dem Patienten mit NYHA II-Herzinsuffizienz. *Therapiewoche* 1989, 39: 3288-3296 [in German]
- Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. *Perfusion* 2000a, 13: 4-15
- Ernst SM. Herb-Drug Interaction Handbook. 1st ed. Church Street Books, Nassau NY 2000b, 109-111
- ESC 2012. Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2012, 33: 1787-1847
- ESC 2021. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021, 42: 3599-3726
- ESCOP. Monographs – The Scientific Foundation for Herbal Medicinal Products, 2. ed. inclusive supplement, European Scientific Cooperation on Phytotherapy. Georg Thieme Verlag, Stuttgart 2003, 98-106
- European Pharmacopoeia 8th ed. Hawthorn leaf and flower. Council of Europe. 01/2010:1432
- European Pharmacopoeia 11th ed. Hawthorn leaf and flower. Council of Europe. 01/2021:1432
- European Pharmacopoeia 8th ed. Hawthorn leaf and flower liquid extract, quantified. Council of Europe. 01/2008:1864
- European Pharmacopoeia 11th ed. Hawthorn leaf and flower liquid extract. Council of Europe. 01/2021:1864
- European Pharmacopoeia 11th ed. Hawthorn leaf and flower dry extract. Council of Europe. 01/2021:1865
- Fehri B, Aiache JM, Boukef K, Memmi A, Hizaoui B. Valeriana officinalis et Crataegus oxyacantha. Toxicite par administrations reitrees et investigations pharmacologiques. *J Pharm Belg* 1991,46: 165-76 [in French]
- Fischer K, Jung F, Koscielny J, Kiesewetter H. Crataegus-Extrakt vs. Methyldigoxin. Einfluss auf Rheology und Mikrozirkulation bei 12 gesunden Probanden. *Münch Med Wochenschr* 1994, 136(Suppl. 1): 35-38 [in German]
- Förster A, Förster K, Bühring M, Wolfstädter HD. Crataegus bei mäßig reduzierter linksventrikulärer Auswurfraction. *Münch Med Wochenschr* 1994, 136(Suppl. 1): 21-26 [in Germany]
- Frishman WH, Grattan JG, Mamtani R. Alternative and complementary medical approaches in the prevention and treatment of cardiovascular disease. *Curr Probl Cardiol* 2005, 30(8): 383-459
- Fürst R, Zirrgiebel U, Totzke F, Zahler S, Vollmar AM, Koch E. The Crataegus extract WS 1442 inhibits balloon catheter-induced intimal hyperplasia in the rat carotid artery by directly influencing PDGFR-beta. *J Atheroscler Res* 2010, 211(2): 409-417
- Garcia-Oliveira P, Fraga-Corral M, Pereira AG, Lourenço-Lopes C, Jimenez-Lopez C, Prieto MA et al. Scientific basis for the industrialization of traditionally used plants of the Rosaceae family. *Food Chem.* 2020, 330: 127197
- Grünwald J, Brendler T, Jaenicke C, editors. PDR for herbal medicines. 4th ed. Thomson Healthcare Inc., Montvale 2007, 279-284

- Härtel S, Kutzner C, Westphal E, Limberger M, Burkart M, Ebner-Priemer U et al. Effects of Endurance Exercise Training and Crataegus Extract WS®1442 in Patients with Heart Failure with Preserved Ejection Fraction – A Randomized Controlled Trial. *Sports* 2014, 2: 59-75
- Halver J, Wenzel K, Sendker J, Carrillo García C, Erdelmeier CAJ, Willems E. Crataegus Extract WS®1442 Stimulates Cardiomyogenesis and Angiogenesis From Stem Cells: A Possible New Pharmacology for Hawthorn? *Front Pharmacol* 2019, 10: 1357. doi: 10.3389/fphar.2019.01357
- Hecker-Niediek AE. Untersuchungen zur Biogenese, Markierung und Pharmakokinetik der Procyanidine aus *Crataegus*-Spezies [Dissertation]. Marburg: Marburg Universität 1983 [in German]
- Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: The SPICE trial. *Eur J Heart Fail* 2008, 10: 1255-1263
- Holubarsch CJF, Colucci WS, Eha J. Benefit-risk assessment of Crataegus extract US 1442: an evidence-based review. *Am J Cardiovasc Drugs* 2018, 18(1): 25-36
- Idris-Khodja N, Auger C, Koch E, Schini-Kerth VB. Crataegus special extract WS®1442 prevents aging-related endothelial dysfunction. *Phytomedicine* 2012, 19(8-9): 699-706
- Jayachandran KS, Khan M, Selvendiran K, Devaraj SN, Kuppusamy P. *Crataegus oxyacantha* extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways. *J Cardiovasc Pharmacol* 2010, 56(5): 526-531
- Kanyonga MP, Faouzi MYA, Zellou A, Essassi M, Cherrah Y. Effects of methanolic extract of *Crataegus oxyacantha* on blood homeostasis in rat. *J Chem Pharm Res* 2011, 3(3): 713-717
- Kaul R. Der Weißdorn. Botanik, Inhaltsstoffe, Qualitätskontrolle, Pharmakologie, Toxikologie und Klinik. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1998, 16-22 [in German]
- Koch E, Malek FA. Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies. *Planta Med* 2011, 77: 1123-1128
- Koch E, Spörl-Aich G. Oral treatment with Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension. *Planta Med* 2006, 72: 1061
- Koller M, Lorenz W, Aubke W, Jensen A, Gerlach FM, Kuhl J et al. Weißdorn-Spezialextrakt in der Therapie früher Stadien der KHK-assoziierten Herzinsuffizienz. *MMW Fortschr Med* 2005, 147(4): 159-164 [in German]
- Kommission E. Monographie: Crataegi folium cum flore (Weißdornblätter mit Blüten). *Bundesanzeiger* Nr. 133, 19 July 1994 [in German]
- Kraft K, Hobbs C. Pocket Guide to Herbal Medicine. Georg Thieme Verlag 2004, 132-133
- Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of *Crataegus oxyacantha* L. *Pharm Pharmacol Lett* 1993, 3: 45-48
- Les Cahier de l'Agence N°3: Médicaments à base de plantes. Agence du Médicament, Paris 1998, 1-88
- Leuchtgens H. Crategus-Spezialextrakt WS 1442 bei Herzinsuffizienz NYHA II. *Fortschr Med* 1993, 111(20/21): 352-354 [in German]
- Liang M, Xu W, Zhang W, Zhang C, Liu R, Shen Y et al. Quantitative LC/MS/MS method and in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactive constituent on cardiovascular system from hawthorn. *Biomed Chromatogr* 2007, 21(4): 422-429

- Ma LY, Liu RH, Xu XD, Yu MQ, Zhang Q, Liu HL. The pharmacokinetics of C-glycosyl flavones of Hawthorn leaf flavonoids in rat after single dose oral administration. *Phytomedicine* 2010, 17(8-9): 640-645
- Madaus G. Lehrbuch der biologischen Heilmittel. Vol 2. Georg Olms Verlag. Hildesheim - New York 1976 (reprint from Madaus G 1938), 1113-1121
- Martinelli F, Perrone A, Yousefi S, Papini A, Castiglione S, Guarino F. Botanical, Phytochemical, Anti-Microbial and Pharmaceutical Characteristics of Hawthorn (*Crataegus monogyna* Jacq.), Rosaceae. *Molecules* 2021, 26(23): 7266. doi: 10.3390/molecules26237266
- Momekov G, Benbassat N. Pharmacological properties of Hawthorn leaf and flower as a cardiovascular agent. *Pharmacia* 2013, 60(1): 24-36
- NCCIH. National Center for Complementary and Integrative Health: Hawthorn. 2020. Available at: <https://www.nccih.nih.gov/health/hawthorn> [accessed 02/2024]
- Niederseer D, Ledl-Kurkowski E, Kvita K, Funk P, Niebauer J. Safety and effects of *Crataegus* extract WS 1442 and Nordic walking on lipid profile and endothelial function: A randomized, partially blinded pilot study in overweight volunteers. *Acta Clin Croat* 2019, 58(4): 604-614
- Occhiuto F, Circosta C, Briguglio F, Tommasini A, De Pasquale A. Étude comparee de l'activite cardiovasculaire des jeunes pousses, des feuilles et des fleurs de *Crataegus xyacantha* L. I. Activite electrique et tension arterielle chez le rat. *Plantes Med Phytother* 1986, 20: 37-51 [in French]
- O'Conolly M, Bernhöft G, Bartsch G. Behandlung älterer, multimorbider Patienten mit stenokardischen Beschwerden. *Therapiewoche* 1987, 37: 3587-3600 [in German]
- O'Conolly M, Jansen W, Bernhöft G, Bartsch G. Behandlung der nachlassenden Herzleistung. *Fortschr Med* 1986, 104(42): 805-808 [in German]
- Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure (review). *Cochrane Database Syst Rev* 2008, Issue 1. Art. No. CD005312 [edited 2009]. Available at <https://www.cochranelibrary.com> [accessed 01/2020]
- Rababa'h AM, Altarabsheh SE, Haddad O, Deo SV, Obeidat Y, Al-Azzam S. Hawthorn Herb Increases the Risk of Bleeding after Cardiac Surgery: An Evidence-Based Approach. *Heart Surg Forum* 2016; 19(4): 175-179
- Rababa'h AM, Al Yacoub ON, El-Elimat T, Rabab'ah M, Altarabsheh S, Deo S et al. The effect of hawthorn flower and leaf extract (*Crataegus* Spp.) on cardiac hemostasis and oxidative parameters in Sprague Dawley rats. *Heliyon* 2020; 6(8): e04617
- Ripperger W. Grundlagen zur praktischen Pflanzenheilkund. Hippokrates-Verlag GmbH Verlag Georg Thieme, Stuttgart-Leipzig 1937, 272-274 [in German]
- Schilcher H, Kammerer S, Wegener T. Leitfaden Phytotherapie, 3. Auflage, Urban & Fischer, München-Jena 2007: 283 [in German]
- Schlegelmilch R, Heywood R. Toxicity of *Crataegus* (hawthorn) extract (WS 1442). *J Am Coll Toxicol* 1994, 13(2): 103-111
- Schmidt U, Kuhn U, Ploch M, Hübner WD. Wirksamkeit des Extraktes LI 132 (600 mg/Tag) bei achtwöchiger Therapie. *Münch Med Wochenschr* 1994, 136(Suppl. 1): 13-19 [in German]

Schmidt-Schweda S, Burstin JV, Möllmann H, Wollner S, Holubarsch C. Der positiv inotrope Effekt des Crataegus Spezialextrakts WS 1442 in isolierten Myozyten aus menschlichem Vorhof- und Ventrikelmuskard wird vorwiegend durch oligomere Procyanidine vermittelt. *Z Kardiologie* 2000, 98(Suppl): 164 [in German]

Schulz H. Vorlesungen über Wirkung und Anwendung der deutschen Arzneipflanzen. Verlag Georg Thieme, Leipzig 1919, 254 [in German]

Schwinger RHG, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. *J Cardiovasc Pharmacol* 2000, 35(5): 700-707

Shatoor AS, Soliman H, Al-Hashem F, El-Gamal B, Othman A, El-Menshawly N. Effect of Hawthorn (*Crataegus aronia* syn. *Azardus* (L)) on platelet function in albino wistar rats. *Thromb Res* 2012, 130: 75-80

Tankanow R, Tamer HR, Streetman DS, Smith SG, Annesley T, Aaronson KD et al. Interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*). *J Clin Pharmacol* 2003, 43: 637-642

Tassell MC, Kingston R, Gilroy D, Lehane M, Furey A. Hawthorn (*Crataegus spp.*) in the treatment of cardiovascular disease. *Pharmacogn Rev* 2010, 4(7): 32-41

Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. *Am Heart J* 2002, 143(5): 910-915

Tauchert M, Gildor A, Lipinski J. Einsatz des hochdosierten Crataegusextraktes WS 1442 in der Therapie der Herzinsuffizienz Stadium NYHA II. *Herz* 1999, 24(6): 465-474 [in German]

Tauchert M, Ploch M, Hübner WD. Wirksamkeit des Weißdorn-Extraktes LI 132 im Vergleich mit Captopril. *Münch Med Wochenschr* 1994, 136(Suppl. 1): 27-33 [in German]

Trexler SE, Nguyen E, Gromek SM, Balunas MJ, Baker WL. Electrocardiographic effects of hawthorn (*Crataegus oxyacantha*) in healthy volunteers: A randomized controlled trial. *Phytother Res* 2018; 32(8): 1642-1646

Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. *Life Sci* 2004, 74(15): 1945-1955

Vogel JHK, Bolling SF, Costello RB, Guarneri EM, Krucoff MW, Longhurst JC et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). *J Am Coll Cardiol* 2005 46(1): 184-221

Weigl A, Assmus KD, Neukum-Schmidt A, Schmitz J, Zapfe G, Noh HS et al. Crataegus-Spezialextrakt WS 1442. *Fortschr Med* 1996, 114(24): 291-296 [in German]

Weigl A, Noh HS. Der Einfluss von Crataegus bei globaler Herzinsuffizienz. *Herz + Gefäß* 1992, 11: 516-524 [in German]

WHO. Monographs on Selected Medicinal Plants. Vol 2. Folium cum Flore Crataegi. World Health Organization. Geneva 2002, 66-82

- Wichtl M. Teedrogen und Phytopharmaka - Ein Handbuch für die Praxis auf wissenschaftlicher Grundlage, 5. ed., Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 2009: 195, 200 [in German]
- Wichtl M. Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1984, 358-360 [in German]
- Williamson E, Driver S, Baxter K, editors. Stockley's herbal medicines interactions. A guide to the interactions of herbal medicines. 2nd ed. Pharmaceutical Press, London 2013, 283-284
- Xia N, Weisenburger S, Koch E, Burkart M, Reifenberg G, Förstermann U et al. Restoration of perivascular adipose tissue function in diet-induced obese mice without changing bodyweight. *Br J Pharmacol* 2017, 174(20): 3443-3453. doi: 10.1111/bph.13703
- Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of hawthorn. *J Ethnopharmacol* 2008, 118: 127-132
- Zapfe jun G. Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II. *Phytomedicine* 2001, 8(4): 262-266
- Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial. *Eur J Heart Fail* 2009, 11: 990-999
- Zorniak M, Szydio B, Krzeminski TF. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences. *J Physiol Pharmacol* 2017, 68(4): 521-526
- Zorniak M, Porc MP, Krzeminski TF. Hawthorn revisited: time- and dose-dependent cardioprotective action of WS-1442 special extract in the reperfusion-induced arrhythmia model in rats in vivo. *J Physiol Pharmacol* 2019, 70(2): doi: 10.26402/jpp.2019.2.14

Literature read but not cited in the AR

- Amel B, Seddik K, Shtaywy A, Saliha D, Mussa AZ, Assia B et al. Phytochemical analysis, antioxidant activity and hypotensive effect of algerian azarole (*Crataegus azarolus* L.) leaves extracts. *Res J Pharm, Biol Chem Sci* 2014, 5(2): 286-305
- Braun R, Zapf T, editors. Standardzulassungen und Standardregistrierungen für Fertigarzneimittel. Weißdornblätter mit Blüten Nr. 1349.99.99 [published 04/1986]. Deutscher Apotheker Verlag, Stuttgart 2022 [in German]
- Bubik MF, Willer EA, Bihari P, Jürgenliemk G, Ammer H, Krombach F et al. A novel approach to prevent endothelial hyperpermeability: the Crataegus extract WS® 1442 targets the cAMP/Rap1 pathway. *J Mol Cell Cardiol* 2012, 52(1): 196-205
- Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In-vitro und In-vivo-Untersuchungen zur kardioprotektiven Wirkung von oligomeren Procyanidinen in einem Crataegus-Extrakt aus Blättern mit Blüten. *Arzneim Forsch/Drug Res* 1997, 47: 821-825
- Chrubasik-Hausmann S. Weißdorn. Crataegus - wirksam bei Herzschwäche. 2020. Available at: http://vu5454.ispcp.adminfrontend.de/wp-content/uploads/2020/04/Weissdorn_-PDF.pdf. [accessed 02/2024; in German]
- Kommission E (Germany) monograph. *Crataegus*. *Bundesanzeiger* Nr. 1, 03 January 1984
- Dood KP, Frey AD, Geisbuhler TP. The effect of Hawthorn extract on the coronary flow. *J Evid Based Complementary Altern Med* 2013, 18(4): 257-267
- Fuchs S, Bischoff I, Willer EA, Bräutigam J, Bubik MF, Erdelmeier CA. The Dual Edema-Preventing Molecular Mechanism of the Crataegus Extract WS 1442 Can Be Assigned to Distinct Phytochemical Fractions. *Planta Med* 2017, 83(8):701-709. doi: 10.1055/s-0042-123388
- Hoppe HA. Drogenkunde. Vol 1. 8th ed. Walter de Gruyter, Berlin – New York 1975, 354-357
- Hwang HS, Boluyt MO, Converso K, Russell MW, Bleske BE. Effects of hawthorn on the progression of heart failure in a rat model of aortic constriction. *Pharmacotherapy* 2009, 29(6): 639-648
- Roddewig C, Hensel H. Reaktion der lokalen Myokarddurchblutung von wachen Hunden und narkotisierten Katzen auf orale und parenterale Applikation einer Crataegusfraktion (oligomere Procyanidine). [Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crataegus fraction (oligomere procyanidines)] *Arzneim-Forsch/Drug Res* 1977; 27: 1407-1410
- Sendker J, Petereit F, Lautenschläger M, Hellenbrand N, Hensel A. Phenylpropanoid-substituted procyanidins and tentatively identified procyanidin glycosides from hawthorn (*Crataegus* spp.). *Planta Med* 2013, 79: 45-51
- Wegrowski JAM, Robert M, Moczar M. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. *Biochem Pharmacol* 1984, 33: 3491-3497